GraphWear, a San Francisco, CA-based company advancing needle-free disease monitoring, raised $20.5m in Series B funding.
The round was led by Mayfield with participation from MissionBio Capital, Builders VC and VSC Ventures.
The company intends to use the funds to accelerate the development and scale of the platform for targets across diabetes, heart disease and cancer detection and grow its team, with plans to recruit across all areas of its business.
Founded by nanotechnology specialists Rajatesh Gudibande and Saurabh Radhakrishnan, GraphWear is advancing a non-invasive method to map patient health without needles, blood or urine. Its disease management platform is enabling clinical trials for the company’s first target, monitoring glucose levels for diabetes, with additional potential across conditions like heart disease and cancer.
Using nanotechnology, GraphWear’s sensor measures molecules like glucose on the surface of the skin. It can then give an accurate read of glucose levels using as little as a few 100 glucose molecules. All of this is done painlessly, without breaking the skin, and with no needle, extraction or lab processing.
FinSMEs
05/10/2021